Ambros Therapeutics’ pain program is moving into public markets through a reverse merger with Werewolf, with the combined company planning a $150 million private placement. The company’s lead asset targets a type of pain that is not responsive to currently available medicines, including opioids, and is described as already approved in Italy but not in the U.S. The transaction structure reflects the sector’s continued reliance on reverse mergers to accelerate liquidity, broaden investor reach, and fund clinical expansion for assets still dependent on U.S. regulatory milestones. For clinicians and competitive planning, the shift to a public platform can change near-term trial resourcing and advisory capacity ahead of U.S. development decisions. The deal also signals that chronic pain—despite historically high bar for endpoints—continues to attract capital when differentiation versus opioid-refractory pain is credible.